Novavax Inc. just scored even more support for its coronavirus vaccine program.
The Gaithersburg company said late Thursday it won a Department of Defense contract worth up to $60 million to help manufacture its Covid-19 vaccine candidate, NVX‑CoV2373. The funding, from the Defense Health Program, would back the production of multiple pieces of the vaccine, to be manufactured in the U.S., according to Novavax’s (NASDAQ: NVAX) announcement.
{iframe}https://www.bizjournals.com/washington/news/2020/06/05/novavax-s-latest-win-a-60m-dod-contract-for-it-c.html{/iframe}